Valosin-containing protein and neurofibromin interact to regulate dendritic spine density.
暂无分享,去创建一个
[1] Jeffrey E. Swensen,et al. Bone resorption in syndromes of the Ras/MAPK pathway , 2011, Clinical genetics.
[2] Yingze Zhang,et al. Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model. , 2011, Bone.
[3] J. Carey,et al. Multiple increased osteoclast functions in individuals with neurofibromatosis type 1 , 2011, American journal of medical genetics. Part A.
[4] P. Robinson,et al. Neurofibromin (Nf1) is required for skeletal muscle development. , 2011, Human molecular genetics.
[5] Y. Jan,et al. Neuronal remodeling and apoptosis require VCP-dependent degradation of the apoptosis inhibitor DIAP1 , 2011, Development.
[6] Patrizia Sola,et al. Exome Sequencing Reveals VCP Mutations as a Cause of Familial ALS , 2011, Neuron.
[7] Sonja W. Scholz,et al. Exome Sequencing Reveals VCP Mutations as a Cause of Familial ALS , 2010, Neuron.
[8] D. Wallace,et al. VCP Associated Inclusion Body Myopathy and Paget Disease of Bone Knock-In Mouse Model Exhibits Tissue Pathology Typical of Human Disease , 2010, PloS one.
[9] B. Blot,et al. CHMP2B mutants linked to frontotemporal dementia impair maturation of dendritic spines , 2010, Journal of Cell Science.
[10] H. Vinters,et al. Synapse loss in dementias , 2010, Journal of neuroscience research.
[11] L. Esser,et al. A novel ATP‐dependent conformation in p97 N–D1 fragment revealed by crystal structures of disease‐related mutants , 2010, The EMBO journal.
[12] A. Wright,et al. Transgenic mice expressing mutant forms VCP/p97 recapitulate the full spectrum of IBMPFD including degeneration in muscle, brain and bone. , 2010, Human molecular genetics.
[13] Richard G. W. Anderson,et al. Sterol-induced Dislocation of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase from Endoplasmic Reticulum Membranes into the Cytosol through a Subcellular Compartment Resembling Lipid Droplets , 2010, The Journal of Biological Chemistry.
[14] J. Taylor,et al. VCP/p97 is essential for maturation of ubiquitin-containing autophagosomes and this function is impaired by mutations that cause IBMPFD , 2010, Autophagy.
[15] J. Ju,et al. p97/VCP at the intersection of the autophagy and the ubiquitin proteasome system , 2010, Autophagy.
[16] J. Nyman,et al. Local Low-Dose Lovastatin Delivery Improves the Bone-Healing Defect Caused by Nf1 Loss of Function in Osteoblasts , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[17] M. Volta,et al. Characterisation of the interaction between syndecan-2, neurofibromin and CASK: dependence of interaction on syndecan dimerization. , 2010, Biochemical and biophysical research communications.
[18] D. Piwnica-Worms,et al. Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease , 2009, The Journal of cell biology.
[19] V. Golubovskaya,et al. Neurofibromin physically interacts with the N‐terminal domain of focal adhesion kinase , 2009, Molecular carcinogenesis.
[20] D. Harats,et al. Dislocation of HMG-CoA reductase and Insig-1, two polytopic endoplasmic reticulum proteins, en route to proteasomal degradation. , 2009, Molecular biology of the cell.
[21] M. Latterich,et al. Hereditary Inclusion Body Myopathy-Linked p97/VCP Mutations in the NH2 Domain and the D1 Ring Modulate p97/VCP ATPase Activity and D2 Ring Conformation , 2009, Molecular and Cellular Biology.
[22] F. Gao,et al. ESCRT, autophagy, and frontotemporal dementia. , 2008, BMB reports.
[23] N. Vij. AAA ATPase p97/VCP: cellular functions, disease and therapeutic potential , 2008, Journal of cellular and molecular medicine.
[24] S. Mundlos,et al. Modelling neurofibromatosis type 1 tibial dysplasia and its treatment with lovastatin , 2008, BMC medicine.
[25] Alcino J. Silva,et al. Effect of Simvastatin on Cognitive Functioning in Children with Neurofibromatosis Type 1 a Randomized Controlled Trial , 2022 .
[26] Yi-Ling Lin,et al. SUMOylation of the MAGUK protein CASK regulates dendritic spinogenesis , 2008, The Journal of cell biology.
[27] J. Hell,et al. NS21: Re-defined and modified supplement B27 for neuronal cultures , 2008, Journal of Neuroscience Methods.
[28] Yi-Ling Lin,et al. Neurofibromin interacts with CRMP-2 and CRMP-4 in rat brain. , 2008, Biochemical and biophysical research communications.
[29] H. Saya,et al. Neurofibromatosis Type 1 (NF1) Tumor Suppressor, Neurofibromin, Regulates the Neuronal Differentiation of PC12 Cells via Its Associating Protein, CRMP-2* , 2008, Journal of Biological Chemistry.
[30] Charles D. Smith,et al. Clinical studies in familial VCP myopathy associated with Paget disease of bone and frontotemporal dementia , 2008, American journal of medical genetics. Part A.
[31] L. Parada,et al. Neurofibromin Is Required for Barrel Formation in the Mouse Somatosensory Cortex , 2008, The Journal of Neuroscience.
[32] A. Kakizuka. Roles of VCP in human neurodegenerative disorders. , 2008, Biochemical Society transactions.
[33] O. Bugiani. The many ways to frontotemporal degeneration and beyond , 2007, Neurological Sciences.
[34] S. Young,et al. ESCRT-III Dysfunction Causes Autophagosome Accumulation and Neurodegeneration , 2007, Current Biology.
[35] Liang Ge,et al. Ufd1 is a cofactor of gp78 and plays a key role in cholesterol metabolism by regulating the stability of HMG-CoA reductase. , 2007, Cell metabolism.
[36] A. Kakizuka,et al. Involvement of valosin‐containing protein (VCP)/p97 in the formation and clearance of abnormal protein aggregates , 2007, Genes to cells : devoted to molecular & cellular mechanisms.
[37] Yi-Ling Lin,et al. Syndecan-2 induces filopodia and dendritic spine formation via the neurofibromin–PKA–Ena/VASP pathway , 2007, The Journal of cell biology.
[38] D. Stephenson,et al. Recent developments in neurofibromatosis type 1 , 2007, Current opinion in neurology.
[39] Hiderou Yoshida,et al. ER stress and diseases , 2007, The FEBS journal.
[40] K. Talbot,et al. Recent advances in the genetics of amyotrophic lateral sclerosis and frontotemporal dementia: common pathways in neurodegenerative disease. , 2006, Human molecular genetics.
[41] W. Hwu,et al. Identification of forty‐five novel and twenty‐three known NF1 mutations in Chinese patients with neurofibromatosis type 1 , 2006, Human mutation.
[42] V. Rybin,et al. HDAC6–p97/VCP controlled polyubiquitin chain turnover , 2006, The EMBO journal.
[43] Charles D. Smith,et al. Novel Ubiquitin Neuropathology in Frontotemporal Dementia With Valosin-Containing Protein Gene Mutations , 2006, Journal of neuropathology and experimental neurology.
[44] Yinghua Zhu,et al. Effect of neurofibromatosis type I mutations on a novel pathway for adenylyl cyclase activation requiring neurofibromin and Ras. , 2006, Human molecular genetics.
[45] W. Westbroek,et al. Neurofibromatosis type 1 protein and amyloid precursor protein interact in normal human melanocytes and colocalize with melanosomes. , 2006, The Journal of investigative dermatology.
[46] J. Tonsgard. Clinical manifestations and management of neurofibromatosis type 1. , 2006, Seminars in pediatric neurology.
[47] M. Sheng,et al. Molecular mechanisms of dendritic spine morphogenesis , 2006, Current Opinion in Neurobiology.
[48] S. Dalal,et al. Inclusion body myopathy-associated mutations in p97/VCP impair endoplasmic reticulum-associated degradation. , 2006, Human molecular genetics.
[49] G. Skibinski. Mutations in the ESCRTIII endosomal complex protein CHMP2B associate with frontotemporal dementia , 2005 .
[50] Alcino J. Silva,et al. The HMG-CoA Reductase Inhibitor Lovastatin Reverses the Learning and Attention Deficits in a Mouse Model of Neurofibromatosis Type 1 , 2005, Current Biology.
[51] A. Dunaevsky,et al. Dendritic spine morphogenesis and plasticity. , 2005, Journal of neurobiology.
[52] Mary B. Kennedy,et al. Spine architecture and synaptic plasticity , 2005, Trends in Neurosciences.
[53] K. Fliessbach,et al. Mutant valosin‐containing protein causes a novel type of frontotemporal dementia , 2005, Annals of neurology.
[54] Elena B. Pasquale,et al. Molecular mechanisms of dendritic spine development and remodeling , 2005, Progress in Neurobiology.
[55] H. Kondo,et al. p97/p47-Mediated biogenesis of Golgi and ER. , 2005, Journal of biochemistry.
[56] Nobumasa Kato,et al. Association between the neurofibromatosis‐1 (NF1) locus and autism in the Japanese population , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[57] Changcheng Song,et al. Molecular perspectives on p97-VCP: progress in understanding its structure and diverse biological functions. , 2004, Journal of structural biology.
[58] A. Pestronk,et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein , 2004, Nature Genetics.
[59] Hisao Kondo,et al. Structural basis of the interaction between the AAA ATPase p97/VCP and its adaptor protein p47 , 2004, The EMBO journal.
[60] H. Saya,et al. PKA phosphorylation and 14‐3‐3 interaction regulate the function of neurofibromatosis type I tumor suppressor, neurofibromin , 2004, FEBS letters.
[61] B. Delabarre,et al. NSF and p97/VCP: similar at first, different at last , 2003, FEBS letters.
[62] P. Woodman. p97, a protein coping with multiple identities , 2003, Journal of Cell Science.
[63] K. Okamoto,et al. Vacuole-creating protein in neurodegenerative diseases in humans , 2003, Neuroscience Letters.
[64] Heike Hering,et al. Lipid Rafts in the Maintenance of Synapses, Dendritic Spines, and Surface AMPA Receptor Stability , 2003, The Journal of Neuroscience.
[65] A. May,et al. Conformational changes of the multifunction p97 AAA ATPase during its ATPase cycle , 2002, Nature Structural Biology.
[66] C. Taxis,et al. Protein dislocation from the ER requires polyubiquitination and the AAA-ATPase Cdc48 , 2002, Nature Cell Biology.
[67] Alcino J. Silva,et al. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1 , 2002, Nature.
[68] M. Sheng,et al. Dentritic spines : structure, dynamics and regulation , 2001, Nature Reviews Neuroscience.
[69] K. Tanaka,et al. VCP/p97 in abnormal protein aggregates, cytoplasmic vacuoles, and cell death, phenotypes relevant to neurodegeneration , 2001, Cell Death and Differentiation.
[70] Chou-Chi H. Li,et al. Valosin-containing protein is a multi-ubiquitin chain-targeting factor required in ubiquitin–proteasome degradation , 2001, Nature Cell Biology.
[71] E. Bigio,et al. Contribution of asymmetric synapse loss to lateralizing clinical deficits in frontotemporal dementias. , 2001, Archives of neurology.
[72] N. Loberto,et al. Changes in the Lipid Turnover, Composition, and Organization, as Sphingolipid-enriched Membrane Domains, in Rat Cerebellar Granule Cells Developing in Vitro * , 2001, The Journal of Biological Chemistry.
[73] M. Sheng,et al. Bipartite Interaction between Neurofibromatosis Type I Protein (Neurofibromin) and Syndecan Transmembrane Heparan Sulfate Proteoglycans , 2001, The Journal of Neuroscience.
[74] H. Saya,et al. Phosphorylation of neurofibromin by cAMP‐dependent protein kinase is regulated via a cellular association of N G,N G‐dimethylarginine dimethylaminohydrolase , 2001, FEBS letters.
[75] L. Parada,et al. Neurofibromin, a tumor suppressor in the nervous system. , 2001, Experimental cell research.
[76] T. Jacks,et al. NF1 Tumor Suppressor Gene Function Narrowing the GAP , 2001, Cell.
[77] D. Vidaud,et al. NF1 gene analysis focused on CpG‐rich exons in a cohort of 93 patients with neurofibromatosis type 1 , 2000, Human mutation.
[78] G Mortier,et al. Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects , 2000, Human mutation.
[79] M. Sheng,et al. Nuclear translocation and transcription regulation by the membrane-associated guanylate kinase CASK/LIN-2 , 2000, Nature.
[80] C. Barthélémy,et al. Association study of the NF1 gene and autistic disorder. , 1999, American journal of medical genetics.
[81] A. Crawford,et al. Neurofibromatosis in children: the role of the orthopaedist. , 1999, The Journal of the American Academy of Orthopaedic Surgeons.
[82] B. Miller,et al. Frontotemporal dementia: Neuropil spheroids and presynaptic terminal degeneration , 1998, Annals of neurology.
[83] D. Longo,et al. Involvement of Valosin-containing Protein, an ATPase Co-purified with IκBα and 26 S Proteasome, in Ubiquitin-Proteasome-mediated Degradation of IκBα* , 1998, The Journal of Biological Chemistry.
[84] D. Longo,et al. Involvement of valosin-containing protein, an ATPase Co-purified with IkappaBalpha and 26 S proteasome, in ubiquitin-proteasome-mediated degradation of IkappaBalpha. , 1998, The Journal of biological chemistry.
[85] A. Brun,et al. Cortical synaptic changes and gliosis in normal aging, Alzheimer's disease and frontal lobe degeneration. , 1996, Dementia.
[86] Robert A. Weinberg,et al. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1 , 1994, Nature Genetics.
[87] D. Price,et al. Synapse loss in the temporal lobe in Alzheimer's disease , 1993, Annals of neurology.
[88] D. Salmon,et al. Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.
[89] S. Sebti,et al. Lovastatin, a cholesterol biosynthesis inhibitor, inhibits the growth of human H-ras oncogene transformed cells in nude mice. , 1991, Cancer communications.
[90] J. Backer,et al. Lovastatin blocks N-ras oncogene-induced neuronal differentiation. , 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[91] B. Brownstein,et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. , 1990, Science.
[92] P. O'Connell,et al. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus , 1990, Cell.
[93] P. O'Connell,et al. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations , 1990, Cell.
[94] S. DeKosky,et al. Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity , 1990, Annals of neurology.
[95] KM Harris,et al. Dendritic spines of CA 1 pyramidal cells in the rat hippocampus: serial electron microscopy with reference to their biophysical characteristics , 1989, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[96] P. Greengard,et al. Synapsin I (protein I), a nerve terminal-specific phosphoprotein. III. Its association with synaptic vesicles studied in a highly purified synaptic vesicle preparation , 1983, The Journal of cell biology.